Related references
Note: Only part of the references are listed.Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease
Niels Vande Casteele et al.
GASTROENTEROLOGY (2015)
157 Fecal Loss of Infliximab As a Cause of Lack of Response in Severe Inflammatory Bowel Disease
Johannan F Brandse et al.
GASTROENTEROLOGY (2015)
A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease
B. G. Levesque et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2014)
Clinical Implications of Measuring Drug and Anti-Drug Antibodies by Different Assays When Optimizing Infliximab Treatment Failure in Crohn's Disease: Post Hoc Analysis of a Randomized Controlled Trial
Casper Steenholdt et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2014)
Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial
Laurent Peyrin-Biroulet et al.
GUT (2014)
Comparison of Outcomes Parameters for Induction of Remission in New Onset Pediatric Crohn's Disease: Evaluation of the Porto IBD Group Growth Relapse and Outcomes with Therapy (GROWTH CD) Study
Arie Levine et al.
INFLAMMATORY BOWEL DISEASES (2014)
A 10-Year, Single Tertiary Care Center Experience on the Durability of Infliximab in Pediatric Inflammatory Bowel Disease
Elaheh Vahabnezhad et al.
INFLAMMATORY BOWEL DISEASES (2014)
Meta-analysis: Fecal Calprotectin for Assessment of Inflammatory Bowel Disease Activity
Jin-Feng Lin et al.
INFLAMMATORY BOWEL DISEASES (2014)
Predictors of response to Infliximab in children with luminal Crohn's disease
Zubin Grover et al.
JOURNAL OF CROHNS & COLITIS (2014)
Trough s-infliximab and antibodies towards infliximab in a cohort of 79 IBD patients with maintenance infliximab treatment
Per Marits et al.
JOURNAL OF CROHNS & COLITIS (2014)
Relationship between serum infliximab trough levels and endoscopic activities in patients with Crohn's disease under scheduled maintenance treatment
Hirotsugu Imaeda et al.
JOURNAL OF GASTROENTEROLOGY (2014)
Outcomes Following Infliximab Therapy for Pediatric Patients Hospitalized With Refractory Colitis-Predominant IBD
Tolulope O. Falaiye et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2014)
Pharmacokinetics of Infliximab in Children with Moderate-to-Severe Ulcerative Colitis: Results from a Randomized, Multicenter, Open-label, Phase 3 Study
Omoniyi J. Adedokun et al.
INFLAMMATORY BOWEL DISEASES (2013)
Long-term outcome of tumor necrosis factor alpha antagonist's treatment in pediatric Crohn's disease
Amit Assa et al.
JOURNAL OF CROHNS & COLITIS (2013)
Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease
Martin Bortlik et al.
JOURNAL OF CROHNS & COLITIS (2013)
Serum infliximab concentrations in pediatric inflammatory bowel disease
Anssi Hamalainen et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2013)
Induction and Maintenance Therapy With Infliximab for Children With Moderate to Severe Ulcerative Colitis
Jeffrey Hyams et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2012)
Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms
Ingrid Ordas et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Therapeutic drug monitoring of biologics for inflammatory bowel disease
Jean-Frederic Colombel et al.
INFLAMMATORY BOWEL DISEASES (2012)
Fecal calprotectin in predicting relapse of inflammatory bowel diseases: A meta-analysis of prospective studies
Ren Mao et al.
INFLAMMATORY BOWEL DISEASES (2012)
The duration of effect of infliximab maintenance treatment in paediatric Crohn's disease is limited
C. I. de Bie et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
Review article: loss of response to anti-TNF treatments in Crohn's disease
S. Ben-Horin et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
Pharmacokinetic Properties of Infliximab in Children and Adults with Crohn's Disease: A Retrospective Analysis of Data from 2 Phase III Clinical Trials
Adedigbo A. Fasanmade et al.
CLINICAL THERAPEUTICS (2011)
The immunogenic part of infliximab is the F(ab ')(2), but measuring antibodies to the intact infliximab molecule is more clinically useful
Shomron Ben-Horin et al.
GUT (2011)
Short Pediatric Crohn's Disease Activity Index for Quality Improvement and Observational Research
Michael D. Kappelman et al.
INFLAMMATORY BOWEL DISEASES (2011)
Long-term Outcome of Treatment with Infliximab in Pediatric-onset Crohn's Disease: A Population-Based Study
Valerie Crombe et al.
INFLAMMATORY BOWEL DISEASES (2011)
Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease
Waqqas Afif et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Tailoring the length of antiviral treatment for hepatitis C
Alessandra Mangia et al.
GUT (2010)
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease.
Jean Frederic Colombel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review
Javier P. Gisbert et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2009)
Long-term Outcome of Maintenance Infliximab Therapy in Children with Crohn's Disease
Jeffrey S. Hyoms et al.
INFLAMMATORY BOWEL DISEASES (2009)
Individual medicine in inflammatory bowel disease: Monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies
Klaus Bendtzen et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2009)
Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: Meta-analysis of placebo-controlled trials
Laurent Peyrin-Biroulet et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2008)
Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease
Johan Van Limbergent et al.
GASTROENTEROLOGY (2008)
Development, validation, and evaluation of a pediatric ulcerative colitis activity index: A prospective multicenter study
Dan Turner et al.
GASTROENTEROLOGY (2007)
Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children
Jeffrey Hyams et al.
GASTROENTEROLOGY (2007)
Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease
Elana A. Maser et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2006)
Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis
GJ Wolbink et al.
ARTHRITIS AND RHEUMATISM (2006)
Infliximab for induction and maintenance therapy for ulcerative colitis
P Rutgeerts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Endoscopy in inflammatory bowel diseases
DW Hommes et al.
GASTROENTEROLOGY (2004)
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease
F Baert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Share Paper
